Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594181 | 0.99 | LMNA (0.38) | ADAMTS5LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1593535 | 0.90 | MAPK1 (0.47) | ADAMTS5LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL14301519 | 0.81 | ADAMTS5 (0.38) | ADAMTS5LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1593272 | 0.79 | NPY5R (0.58) | ADRA2ANPY5RMAPTALDH1A1 | |
| SCHEMBL1593554 | 0.78 | NPY5R (0.57) | ADRA2ANPY5RMAPTALDH1A1 | |
| SCHEMBL7068273 | 0.78 | ADAMTS5 (0.35) | ADAMTS5LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1593533 | 0.75 | MAPK1 (0.42) | LMNAMEN1KMT2AMAPK1PIK3CD | |
| SCHEMBL1594423 | 0.72 | NPY5R (0.54) | MEN1KMT2APIK3CDPIK3R1PIK3CA | |
| SCHEMBL7547272 | 0.72 | MAPK1 (0.40) | LMNAMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL1594090 | 0.72 | NPY5R (0.54) | ADRA2ANPY5RMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| EP-1499277-A4 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-11 | — | — | US | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1499277-A2 | MODIFICATION OF FEEDING BEHAVIOR | Imperial College Innovations Limited (GB) | 2005-01-26 | — | — | EP | disclosed |
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6569856-B2 | Treatment of feeding disorders, obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, cardiovascular disorders, sleep disturbances | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-05-27 | — | — | US | disclosed |
| WO-2003026591-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2003-04-03 | — | — | WO | disclosed |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6340683-B1 | NEUROPEPTIDE Y ANTAGONISTS; TREATING EATING DISORDERS, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | ADAMTS5 550/4885LMNA 4620/4885MEN1 2160/4885 |
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NPY4R, NPY2R, NPY1R | ADAMTS5 2690/4885LMNA 4483/4885MEN1 1736/4885 |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | ADAMTS5 2534/4885LMNA 4120/4885MEN1 1419/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | ADAMTS5 605/4885LMNA 4406/4885MEN1 3247/4885 |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | ADAMTS5 550/4885LMNA 4620/4885MEN1 2160/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | ADAMTS5 605/4885LMNA 4406/4885MEN1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.